Amen Ness1, Todd Dias, Karla Damus, Irina Burd, Vincenzo Berghella. 1. Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA, USA.
Abstract
OBJECTIVE: The purpose of this study was to determine whether current attitudes regarding the use of progesterone to prevent preterm birth have changed since our last survey in 2003. STUDY DESIGN: We mailed a 20 question survey to 1264 board certified Maternal-Fetal Medicine specialists in the United States between February and March of 2005 asking about their use and attitudes regarding progesterone to prevent preterm birth. RESULTS: Five hundred and seventy-two surveys were returned (response rate of 45%). In 2005, 67% of respondents used progesterone to prevent SPTB, compared to 38% in 2003 (P < .001). Among users, 38% recommended progesterone for indications other than previous SPTB. Users were more concerned about lack of insurance coverage compared to nonusers but nonusers were more concerned about safety, efficacy, need for more data, and long-term neonatal effects. CONCLUSION: Although the use of progesterone to prevent PTB has increased significantly since our last survey, there remain a substantial number of nonusers. Among users, many are using it for indications not yet proven in clinical trials. Current nonusers have higher levels of concerns compared to nonusers in the first survey and their major concern is the need for more data.
OBJECTIVE: The purpose of this study was to determine whether current attitudes regarding the use of progesterone to prevent preterm birth have changed since our last survey in 2003. STUDY DESIGN: We mailed a 20 question survey to 1264 board certified Maternal-Fetal Medicine specialists in the United States between February and March of 2005 asking about their use and attitudes regarding progesterone to prevent preterm birth. RESULTS: Five hundred and seventy-two surveys were returned (response rate of 45%). In 2005, 67% of respondents used progesterone to prevent SPTB, compared to 38% in 2003 (P < .001). Among users, 38% recommended progesterone for indications other than previous SPTB. Users were more concerned about lack of insurance coverage compared to nonusers but nonusers were more concerned about safety, efficacy, need for more data, and long-term neonatal effects. CONCLUSION: Although the use of progesterone to prevent PTB has increased significantly since our last survey, there remain a substantial number of nonusers. Among users, many are using it for indications not yet proven in clinical trials. Current nonusers have higher levels of concerns compared to nonusers in the first survey and their major concern is the need for more data.
Authors: Amy L Turitz; Jamie A Bastek; Stephanie E Purisch; Michal A Elovitz; Lisa D Levine Journal: Am J Obstet Gynecol Date: 2015-10-28 Impact factor: 8.661
Authors: Miha Lucovnik; Ruben J Kuon; Linda R Chambliss; William L Maner; Shao-Qing Shi; Leili Shi; James Balducci; Robert E Garfield Journal: Acta Obstet Gynecol Scand Date: 2011-06-27 Impact factor: 3.636
Authors: Helen Christine McNamara; Rachael Wood; James Chalmers; Neil Marlow; John Norrie; Graeme MacLennan; Gladys McPherson; Charles Boachie; Jane Elizabeth Norman Journal: PLoS One Date: 2015-04-16 Impact factor: 3.240